MX2018011046A - Composiciones y metodos para tratar canceres. - Google Patents
Composiciones y metodos para tratar canceres.Info
- Publication number
- MX2018011046A MX2018011046A MX2018011046A MX2018011046A MX2018011046A MX 2018011046 A MX2018011046 A MX 2018011046A MX 2018011046 A MX2018011046 A MX 2018011046A MX 2018011046 A MX2018011046 A MX 2018011046A MX 2018011046 A MX2018011046 A MX 2018011046A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- treating cancers
- galectin
- aml
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4726—Lectins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1732—Lectins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composiciones y métodos para tratar cánceres sólidos y hematológicos, que incluyen leucemia mieloide aguda (AML), se proporcionan en este documento. Los métodos incluyen administrar formas negativas dominantes, truncadas de galectina-3.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662308045P | 2016-03-14 | 2016-03-14 | |
PCT/US2017/022168 WO2017160761A2 (en) | 2016-03-14 | 2017-03-13 | Compositions and methods for treating cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018011046A true MX2018011046A (es) | 2019-05-06 |
Family
ID=59851561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018011046A MX2018011046A (es) | 2016-03-14 | 2017-03-13 | Composiciones y metodos para tratar canceres. |
Country Status (5)
Country | Link |
---|---|
US (1) | US10717774B2 (es) |
EP (1) | EP3429613A4 (es) |
CN (1) | CN109310738A (es) |
MX (1) | MX2018011046A (es) |
WO (1) | WO2017160761A2 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10717774B2 (en) | 2016-03-14 | 2020-07-21 | Kiromic, Inc. | Compositions and methods for treating cancers |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
EP3883560A1 (en) * | 2018-11-19 | 2021-09-29 | Unichem Laboratories Limited | Combination of chemotherapy with recombinant s. rolfsii lectin |
US20230000896A1 (en) * | 2019-12-09 | 2023-01-05 | President And Fellows Of Harvard College | Aldh3a2 inhibition and ferroptosis induction for cancer therapy |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6770622B2 (en) * | 2001-06-08 | 2004-08-03 | Gary A. Jarvis | N-terminally truncated galectin-3 for use in treating cancer |
US20040023855A1 (en) | 2002-04-08 | 2004-02-05 | John Constance M. | Biologic modulations with nanoparticles |
US7780912B2 (en) * | 2005-08-26 | 2010-08-24 | Lawrence Livermore National Security, Llc | Paint for detection of radiological or chemical agents |
EP2120050A1 (en) * | 2008-05-15 | 2009-11-18 | Steinbeis-Transferzentrum Biopolymeranalytik/Proteomics und Proteinchemie | Identification of ligand recognition domains |
US8921317B1 (en) | 2009-06-12 | 2014-12-30 | Bae Systems Information And Electronic Systems Integration Inc. | Nano-recombinant fibrinogen for fibrin sealants |
US9272014B2 (en) | 2011-03-29 | 2016-03-01 | Texas Tech University System | Galectin-3C combination therapy for human cancer |
CA2868391A1 (en) | 2012-04-02 | 2013-10-10 | Stephane Bancel | Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same |
WO2014127275A2 (en) | 2013-02-15 | 2014-08-21 | Avraham Raz | Galectin-3 as a marker for prostate cancer |
WO2015051850A1 (en) | 2013-10-11 | 2015-04-16 | Universität Für Bodenkultur Wien | Compositions containing galectin-3 modulators for the treatment of bone disorders |
EP3076989A4 (en) | 2013-12-05 | 2017-05-03 | Texas Tech University System | Galectin-3 to treat ovarian cancer |
JP2017507128A (ja) | 2014-02-03 | 2017-03-16 | テキサス テック ユニヴァーシティー システムTexas Tech University System | ガレクチン−3阻害剤(gal−3m)は、プロテアソーム阻害剤と組み合わせて使用した場合、相加的な抗骨髄腫及び抗固形腫瘍効果、破骨細胞形成の減少及び器官保護と関係する |
US10717774B2 (en) | 2016-03-14 | 2020-07-21 | Kiromic, Inc. | Compositions and methods for treating cancers |
-
2017
- 2017-03-13 US US16/082,363 patent/US10717774B2/en active Active
- 2017-03-13 CN CN201780017624.6A patent/CN109310738A/zh active Pending
- 2017-03-13 WO PCT/US2017/022168 patent/WO2017160761A2/en active Application Filing
- 2017-03-13 MX MX2018011046A patent/MX2018011046A/es unknown
- 2017-03-13 EP EP17767289.6A patent/EP3429613A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US20190031732A1 (en) | 2019-01-31 |
WO2017160761A2 (en) | 2017-09-21 |
EP3429613A4 (en) | 2020-01-15 |
EP3429613A2 (en) | 2019-01-23 |
WO2017160761A3 (en) | 2017-12-07 |
CN109310738A (zh) | 2019-02-05 |
US10717774B2 (en) | 2020-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023007841A (es) | Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer. | |
MX2018011046A (es) | Composiciones y metodos para tratar canceres. | |
PH12017502002A1 (en) | 5`-substituted nucleoside analogs | |
MX2019003938A (es) | Compuestos espirociclicos. | |
MX2018006240A (es) | Composiciones que comprenden cepas bacterianas. | |
NZ746554A (en) | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | |
MY198613A (en) | Nitrobenzyl derivatives of anti-cancer agents | |
PH12018502535A1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
DK3140319T3 (en) | Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml) | |
PH12019502138A1 (en) | Compounds and compositions for treating hematological disorders | |
MX2023010882A (es) | Compuestos y composiciones para el tratamiento de trastornos hematológicos. | |
MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
MX2019005349A (es) | Uso de analogos de sangliferina macrociclicos como compuestos anticancerigenos. | |
WO2017096303A3 (en) | Cerdulatinib for treating hematological cancers | |
MX2017012553A (es) | Compuestos espirociclicos. | |
MX2019010492A (es) | Kits y metodos para preparar composiciones de plaquetas con patogeno inactivado. | |
EP3847283A4 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER INDUCED CANCERS | |
MX2019001979A (es) | Agonista de ppar? para el tratamiento de neoplasias hematicas. | |
MX2016015568A (es) | Derivados de nucleosidos para el tratamiento del cancer. | |
WO2015181624A3 (en) | Nucleoside derivatives for the treatment of cancer | |
WO2016130581A8 (en) | Combination cancer therapy | |
MX2021008834A (es) | Metodos de tratamiento del cancer de mama con tucatinib. | |
EP3615020A4 (en) | METHODS, AGENTS AND COMPOSITIONS FOR TREATMENT OF ACUTE MYELOIC LEUKEMIA | |
JOP20150008B1 (ar) | أجسام مضادة ل vista وأجزاء منها |